HER2
View/Edit Human | View/Edit Mouse |
Receptor tyrosine-protein kinase erbB-2 is a protein that normally resides in the membranes of cells and is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene originally isolated from the avian genome. The human protein is also frequently referred to as HER2 (human epidermal growth factor receptor 2) or CD340 (cluster of differentiation 340).[5][6][7]
HER2 is a member of the human
Name
HER2 is so named because it has a similar structure to human epidermal growth factor receptor, or
Gene
ERBB2, a known
Function
The ErbB family consists of four individual plasma membrane-bound receptor tyrosine kinases. One of which is erbB-2, and the other members being erbB-1, erbB-3 (neuregulin-binding; lacks kinase domain), and erbB-4. All four contain an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity. Notably, no ligands for HER2 have yet been identified.[11][12] HER2 can heterodimerise with any of the other three receptors and is considered to be the preferred dimerisation partner of the other ErbB receptors.[13]
Dimerisation results in the autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptors and initiates a variety of signaling pathways.
Signal transduction
Signaling pathways activated by HER2 include:[14]
- mitogen-activated protein kinase (MAPK)
- phosphoinositide 3-kinase (PI3K/Akt)
- phospholipase C γ
- protein kinase C (PKC)
- Signal transducer and activator of transcription (STAT)
In summary, signaling through the ErbB family of receptors promotes cell proliferation and opposes apoptosis, and therefore must be tightly regulated to prevent uncontrolled cell growth from occurring.
Clinical significance
Cancer
Amplification, also known as the over-expression of the ERBB2 gene, occurs in approximately 15-30% of
HER2 is colocalised and most of the time, coamplified with the gene GRB7, which is a proto-oncogene associated with breast, testicular germ cell, gastric, and esophageal tumours.
HER2 proteins have been shown to form clusters in cell membranes that may play a role in tumorigenesis.[24][25]
Evidence has also implicated HER2 signaling in resistance to the EGFR-targeted cancer drug cetuximab.[26]
The high expression of HER2 correlates with better survival in esophageal adenocarcinoma.[27]
The high amplification of HER2 copy number positively contributes to the survival time of gastric cardia adenocarcinoma patients.[28]
Mutations
Furthermore, diverse structural alterations have been identified that cause ligand-independent firing of this receptor, doing so in the absence of receptor over-expression. HER2 is found in a variety of tumours and some of these tumours carry point mutations in the sequence specifying the transmembrane domain of HER2. Substitution of a valine for a glutamic acid or a glutamine in the transmembrane domain can result in the constitutive dimerisation of this protein in the absence of a ligand.[29]
HER2 mutations have been found in non-small-cell lung cancers (NSCLC) and can direct treatment.[30]
As a drug target
HER2 is the target of the
An important downstream effect of trastuzumab binding to HER2 is an increase in p27, a protein that halts cell proliferation.[33] Another monoclonal antibody, Pertuzumab, which inhibits dimerisation of HER2 and HER3 receptors, was approved by the FDA for use in combination with trastuzumab in June 2012.
As of November 2015, there are a number of ongoing and recently completed clinical trials of novel targeted agents for HER2+ metastatic breast cancer, e.g. margetuximab.[34]
Additionally, NeuVax (Galena Biopharma) is a peptide-based immunotherapy that directs "killer" T cells to target and destroy cancer cells that express HER2. It has entered phase 3 clinical trials.
It has been found that patients with ER+ (Estrogen receptor positive)/HER2+ compared with ER-/HER2+ breast cancers may actually benefit more from drugs that inhibit the PI3K/AKT molecular pathway.[35]
Over-expression of HER2 can also be suppressed by the amplification of other genes. Research is currently being conducted to discover which genes may have this desired effect.
The expression of HER2 is regulated by signaling through estrogen receptors. Normally,
Among approved anti-HER2 therapeutics are also tyrosine kinase inhibitors (
Diagnostics
HER2 testing is performed on breast biopsy of breast cancer patients to assess prognosis and to determine suitability for trastuzumab therapy. It is important that trastuzumab is restricted to HER2-positive individuals as it is expensive and has been associated with cardiac toxicity.[39] For HER2-positive tumors, the benefits of trastuzumab clearly outweigh the risks.
Tests are usually performed on breast biopsy samples obtained by either fine-needle aspiration, core needle biopsy, vacuum-assisted breast biopsy, or surgical excision.
Immunohistochemistry
By immunohistochemistry, the sample is given a score based on the cell membrane staining pattern.
Score[41][42] | Pattern[43] | Status[41][42] |
---|---|---|
0 | Either:[43]
|
HER2 negative (not present) |
1+ | Incomplete membrane staining that is faint or barely perceptible and within >10% of the invasive tumor cells.[43] | |
2+ | Weak to moderate complete membrane staining observed in >10% of tumor cells.[43] | Borderline/Equivocal |
3+ | Circumferential membrane staining that is complete, intense, and in >10% of tumor cells.[43] | HER2 positive |
Micrographs showing each score:[44]
-
0
-
1+
-
2+
-
3+
Fluorescence in situ hybridisation
FISH can be used to measure the number of copies of the gene which are present and is thought to be more reliable than immunohistochemistry.[45] It usually uses chromosome enumeration probe 17 (CEP17) to count the amount of chromosomes. Hence, the HER2/CEP17 ratio reflects any amplification of HER2 as compared to the number of chromosomes. The signals of 20 cells are usually counted.
-
This cell displays 2 signals of HER2 (red) and 3 signals of CEP17 (green)
-
Two signals that are closer to each other than the signal diameter count as one.
-
One of these signals is too faint, and is presumably debris.
-
Cells with only one type of signal are excluded from the count.
-
Overlapping cells are also excluded from the count.
-
A yellow signal counts as one red and one green (which are overlapping)
-
Algorithm for the evaluation of HER2 on fluorescence in situ hybridization (FISH).[46]
HER2/CEP17 ratio | |||
---|---|---|---|
≥2.0 | <2.0 | ||
Average HER2 copy number per cell | ≥4.0 | HER2 positive | Additional work-up required |
<4.0 | Additional work-up required | HER2 negative |
If the initial HER2 result is negative for a needle biopsy of a primary breast cancer, a new HER2 test may be performed on the subsequent breast excision.[46]
Serum
The extracellular domain of HER2 can be shed from the surface of tumour cells and enter the circulation. Measurement of serum HER2 by enzyme-linked immunosorbent assay (ELISA) offers a far less invasive method of determining HER2 status than a biopsy and consequently has been extensively investigated. Results so far have suggested that changes in serum HER2 concentrations may be useful in predicting response to trastuzumab therapy.[47] However, its ability to determine eligibility for trastuzumab therapy is less clear.[48]
Interactions
HER2/neu has been shown to
See also
- SkBr3 Cell Line, over-expresses HER2
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000141736 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000062312 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "ERBB2 erb-b2 receptor tyrosine kinase 2 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2016-06-14.
- ^ "ERBB2". Genetics Home Reference. Retrieved 2016-06-19.
- ISBN 978-1-4665-6939-3.
- PMID 27913999.
- ^ PMID 23320171.
- PMID 2999974.
- PMID 11960991.
- PMID 11585755.
- PMID 11737890.
- S2CID 207242039.
- S2CID 26675265.
- PMID 17993237.
- ISBN 978-1-4377-1781-5.
- ISBN 978-1-4377-1781-5.
- S2CID 25674060.
- PMID 24576030.
- PMID 22222640.
- PMID 21556317.
- S2CID 34106002.
- PMID 10318765.
- S2CID 2119158.
- PMID 21900593.
- PMID 30621632.
- PMID 34764264.
- PMID 1978329.
- S2CID 37663670.
- PMID 25848335.
- ISBN 978-1-259-64403-0.
- PMID 15611642.
- PMID 26557900.
- / lay-source = ScienceDaily
- ^ "Study sheds new light on tamoxifen resistance". Cordis News. Cordis. 2008-11-13. Archived from the original on 2009-02-20. Retrieved 2008-11-14.
- PMID 19005469.
- PMID 32530388.
- PMID 17687157.
- PMID 27899970.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - ^ a b "IHC Tests (ImmunoHistoChemistry)". Breastcancer.org. Retrieved 2019-10-04. Last modified on October 23, 2015
- ^ PMID 25276427.
- ^ PMID 31693827.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - PMID 22647525.)"
- "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0 - ^ Giuliano AE, Hurvitz SA (2019). "Breast Disorder". In Papadakis MA, McPhee SJ, Rabow MW (eds.). Current Medical Diagnosis & Treatment. New York, NY: McGraw-Hill.
- ^ S2CID 44143975.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - S2CID 7307111.
- PMID 19255335.
- PMID 11950845.
- PMID 11245482.
- PMID 7702605.
- S2CID 1429113.
- ^ PMID 11278603.
- S2CID 19749569.
- PMID 12379659.
- ^ PMID 16729043.
- PMID 11606575.
- ^ PMID 9710588.
- PMID 11071886.
- PMID 18655187.
- S2CID 19754641.
- PMID 12939402.
- PMID 11278868.
- PMID 1334406.
- PMID 1676673.
- PMID 1683701.
- PMID 10085134.
Further reading
- Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. (2003). "The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy". The Oncologist. 8 (4): 307–325. S2CID 1055491.
- Zhou BP, Hung MC (October 2003). "Dysregulation of cellular signaling by HER2/neu in breast cancer". Seminars in Oncology. 30 (5 Suppl 16): 38–48. PMID 14613025.
- Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E (December 2004). "Role of HER2/neu in tumor progression and therapy". Cellular and Molecular Life Sciences. 61 (23): 2965–2978. S2CID 37611938.
- Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T (June 2006). "Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy". World Journal of Gastroenterology. 12 (21): 3297–3305. PMID 16733844.
- Laudadio J, Quigley DI, Tubbs R, Wolff DJ (January 2007). "HER2 testing: a review of detection methodologies and their clinical performance". Expert Review of Molecular Diagnostics. 7 (1): 53–64. S2CID 9971746.
- Bianchi F, Tagliabue E, Ménard S, Campiglio M (March 2007). "Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections". Cell Cycle. 6 (6): 643–646. PMID 17374991.
External links
- AACR Cancer Concepts Factsheet on HER2
- Breast Friends for Life Network - A South African Breast Cancer Support Forum for HER2 Positive Women
- HerceptinR : Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients. Sci. Rep. 4:4483
- Receptor,+erbB-2 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- PDBe-KB provides an overview of all the structure information available in the PDB for Human Receptor tyrosine-protein kinase erbB-2